<DOC>
	<DOC>NCT01972568</DOC>
	<brief_summary>This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).</brief_summary>
	<brief_title>Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Eligible male and female subjects, aged 18 years or older Must have at least moderately active SLE, as defined as SLE Disease Activity Index2000 (SLEDAI2K) score greater than or equal to [&gt;=] 6 at screening visit At least 4 of the 11 American college of rheumatology (ACR) classification criteria for SLE (diagnosed &gt;= 6 months prior to the screening visit) Be seropositive for antinuclear antibodies (ANA) and/or antidoublestranded deoxyribonucleic acid (antidsDNA) antibodies Other protocol defined inclusion criteria could apply Subjects have demyelinating disorder Severe central nervous system SLE Use of cyclophosphamide within 3 months of the screening visit Urine protein:creatinine ratio (UPCr) &gt;= 2 milligram per milligram (mg/mg) per day Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atacicept 75 and 150 mg</keyword>
	<keyword>Placebo</keyword>
</DOC>